103 related articles for article (PubMed ID: 18679062)
1. Changes in gene expression of gastric mucosa during therapeutic acid inhibition.
Nørsett KG; Laegreid A; Kusnierczyk W; Langaas M; Ylving S; Fossmark R; Myhre S; Falkmer S; Waldum HL; Sandvik AK
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):613-23. PubMed ID: 18679062
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of rat gastric mucosal response to potent acid inhibition.
Nørsett KG; Laegreid A; Langaas M; Wörlund S; Fossmark R; Waldum HL; Sandvik AK
Physiol Genomics; 2005 Jun; 22(1):24-32. PubMed ID: 15827235
[TBL] [Abstract][Full Text] [Related]
3. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial.
Fiocca R; Mastracci L; Attwood SE; Ell C; Galmiche JP; Hatlebakk J; Bärthel A; Långström G; Lind T; Lundell L;
Aliment Pharmacol Ther; 2012 Nov; 36(10):959-71. PubMed ID: 22998687
[TBL] [Abstract][Full Text] [Related]
4. Gastric carcinoids after long-term use of a proton pump inhibitor.
Jianu CS; Fossmark R; Viset T; Qvigstad G; Sørdal O; Mårvik R; Waldum HL
Aliment Pharmacol Ther; 2012 Oct; 36(7):644-9. PubMed ID: 22861200
[TBL] [Abstract][Full Text] [Related]
5. Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole.
Hage E; Hendel L; Gustafsen J; Hendel J
Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):781-9. PubMed ID: 12811309
[TBL] [Abstract][Full Text] [Related]
6. Esomeprazole reduces gastroesophageal reflux after beer consumption in healthy volunteers.
Franke A; Hepp C; Harder H; Beglinger C; Singer MV
Scand J Gastroenterol; 2008; 43(12):1425-31. PubMed ID: 18924018
[TBL] [Abstract][Full Text] [Related]
7. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
Jensen RT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):4-19. PubMed ID: 16433886
[TBL] [Abstract][Full Text] [Related]
8. Effect of proton pump inhibition on the gastric volume: assessed by magnetic resonance imaging.
Babaei A; Bhargava V; Aalam S; Scadeng M; Mittal RK
Aliment Pharmacol Ther; 2009 Apr; 29(8):863-70. PubMed ID: 19170660
[TBL] [Abstract][Full Text] [Related]
9. Effects of 6-12 months of esomeprazole treatment on the gastric mucosa.
Genta RM; Rindi G; Fiocca R; Magner DJ; D'Amico D; Levine DS
Am J Gastroenterol; 2003 Jun; 98(6):1257-65. PubMed ID: 12818266
[TBL] [Abstract][Full Text] [Related]
10. Morphological changes of the human gastric mucosa under long-term proton pump inhibitor therapy and their clinical relevance.
Lamberts R
Microsc Res Tech; 2000 Mar; 48(6):357-66. PubMed ID: 10738317
[TBL] [Abstract][Full Text] [Related]
11. Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase.
Mullin JM; Valenzano MC; Whitby M; Lurie D; Schmidt JD; Jain V; Tully O; Kearney K; Lazowick D; Mercogliano G; Thornton JJ
Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1317-25. PubMed ID: 18684245
[TBL] [Abstract][Full Text] [Related]
12. The effects of high-dose esomeprazole on gastric and oesophageal acid exposure and molecular markers in Barrett's oesophagus.
Abu-Sneineh A; Tam W; Schoeman M; Fraser R; Ruszkiewicz AR; Smith E; Drew PA; Dent J; Holloway RH
Aliment Pharmacol Ther; 2010 Oct; 32(8):1023-30. PubMed ID: 20937048
[TBL] [Abstract][Full Text] [Related]
13. Esomeprazole: a proton pump inhibitor.
Vachhani R; Olds G; Velanovich V
Expert Rev Gastroenterol Hepatol; 2009 Feb; 3(1):15-27. PubMed ID: 19210109
[TBL] [Abstract][Full Text] [Related]
14. Quantitative assessment of gastric corpus atrophy in subjects using omeprazole: a randomized follow-up study.
van Grieken NC; Meijer GA; Weiss MM; Bloemena E; Lindeman J; Baak JP; Meuwissen SG; Kuipers EJ
Am J Gastroenterol; 2001 Oct; 96(10):2882-6. PubMed ID: 11693321
[TBL] [Abstract][Full Text] [Related]
15. No parietal cell hypertrophy of the metaplastic corpus mucosa in the distal esophagus under PPI treatment.
Stolte M
Pathol Res Pract; 2010 Jan; 206(1):51-2. PubMed ID: 19664886
[TBL] [Abstract][Full Text] [Related]
16. Relationship between symptom response and esophageal pH level on standard dose of esomeprazole treatment for gastroesophageal reflux disease.
Peng S; Xiong LS; Xiao YL; Wang AJ; Lin JK; Hu PJ; Chen MH
Chin Med J (Engl); 2010 Aug; 123(15):2012-7. PubMed ID: 20819534
[TBL] [Abstract][Full Text] [Related]
17. Evolving issues in the management of reflux disease?
Yuan Y; Hunt RH
Curr Opin Gastroenterol; 2009 Jul; 25(4):342-51. PubMed ID: 19417644
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system.
Vasiliadis KV; Viazis N; Vlachogiannakos J; Sgouros SN; Stefanidis G; Archimandritis A; Karamanolis DG
Am J Gastroenterol; 2010 Feb; 105(2):308-13. PubMed ID: 19809412
[TBL] [Abstract][Full Text] [Related]
19. Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five-year prospective study in community medicine.
Miyamoto M; Haruma K; Kuwabara M; Nagano M; Okamoto T; Tanaka M
J Gastroenterol Hepatol; 2007 May; 22(5):639-44. PubMed ID: 17444849
[TBL] [Abstract][Full Text] [Related]
20. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.
Park W; Hicks DM; Khandwala F; Richter JE; Abelson TI; Milstein C; Vaezi MF
Laryngoscope; 2005 Jul; 115(7):1230-8. PubMed ID: 15995512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
